Zealand announces positive results with glucagon analogue
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article8301163.ece/ALTERNATES/schema-16_9/Adam%2520Steensberg2-version2.jpg)
During the summer, the Danish biotech company Zealand Pharma will have a number of important phase II trials coming up, as CEO Britt Mellby Jensen told MedWatch recently.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand Pharma preparing for US expansion
For abonnenter
Zealand earns USD 10m on EU approval of diabetes combo
For abonnenter
Zealand moves US collaboration into phase II
For abonnenter